Cellares to provide proof-of-concept manufacturing for a key BMS CAR-T cell therapy Cellares' proprietary Cell Shuttle is a cost-efficient, reliable, fully automated, and highly scalable manufacturing ...

Cellares, an Integrated Development and Manufacturing Organization (IDMO), concluded the Technology Adoption Program (TAP) on its automated cell therapy manufacturing Cell Shuttle™ for resecabtagene ...

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle ...

Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX) ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

FDA's Adam Fisher speaks at the 2026 REdI meeting. (Source: REdI) Adam Fisher, the staff director of the Office of Pharmaceutical Quality in the Center for Drug Evaluation and Research (CDER) at the ...

In the decade since the creation of the Manufacturing USA Program, the importance of advanced manufacturing leadership remains high for U.S. economic and national security. This study will recommend ...

WASHINGTON — To better compete globally, the United States should develop a comprehensive industrial strategy to align resources for manufacturing and maximize the national security and economic ...

Proof-of-concept manufacturing to be provided by Cellares for a key Lyell CAR T-cell therapy using Cellares' exclusive Cell Shuttle Collaboration to evaluate potential utilization of the Cell Shuttle ...

Cellares will automate the TSC-101 manufacturing and testing processes on the Cell Shuttle and the Cell Q automated testing ...